In MPN patients, TET2 occurs in 7–22% and 19–28% of patients in chronic phase and blast phase, respectively, suggesting that TET2 mutations could have a role in increase the risk of leukemic transformation [54]. This evidence concerns the gene TET2 and myeloproliferative neoplasm.